Invitation to presentation of the Q3 Interim Report, on November 3 at 2 pm CET
Uppsala, Sweden – October 25, 2022 – As previously communicated Orexo will announce the Q3 2022 Interim Report on November 3 at 8 am CET. The same day at 2 pm, analysts, investors, and media are invited to attend a presentation where Nikolaj Sørensen, CEO, Fredrik Järrsten, CFO, and Robert Rönn, SVP and Head of R&D will present the latest development.
After the presentation a Q&A will be held. Questions can also be sent in advance to firstname.lastname@example.org, not later than 11 am CET. Dependent on time at the call these questions will be raised on the call or responded by email.
Please view the instructions below on how to participate.
Telephone no.: SE: +46 8 505 58 353 UK: +44 333 300 9263 US: +16 467 224 956
Prior to the event the presentation material will be available on the website under Investors/Reports, Presentations
For further information, please contact:
Orexo AB (publ.)
Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00
Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product ZUBSOLV® for treatment of opioid use disorder. Total net sales for 2021 amounted to SEK 565 million and the number of employees was 121. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.